Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | PFKFB3 | Q16875 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | BCKDK | O14874 | 2/20 | 0.40 |
| ▸ | PFKFB4 | Q16877 | 3/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8877598 | 0.80 | MCL1 (0.56) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1255148 | 0.78 | BCKDK (0.58) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1254412 | 0.77 | MCL1 (0.51) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9613232 | 0.77 | MCL1 (0.66) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13881349 | 0.77 | MCL1 (0.50) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1447569 | 0.76 | PRNP (0.60) | ALDH1A1MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL12581557 | 0.75 | MCL1 (0.41) | MCL1BCL2L1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12553241 | 0.75 | MCL1 (0.41) | MCL1BCL2L1ALDH1A1MAPTNPC1 | |
| SCHEMBL12894484 | 0.75 | PFKFB3 (0.47) | PFKFB3ALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL9613234 | 0.75 | PFKFB3 (0.56) | MCL1BCL2L1PFKFB3RXFP1PFKFB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MCL1 3332/4885BCL2L1 1188/4885PFKFB3 4275/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MCL1 3332/4885BCL2L1 1188/4885PFKFB3 4275/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | MCL1 3332/4885BCL2L1 1188/4885PFKFB3 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.